Search Results
Your search for ,USE matches 11256 pages
Showing 3751 - 3800Breast Induration With Hypofractionated vs Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma in Situ
In a Danish Breast Cancer Group phase III trial (DBCG HYPO) reported in the Journal of Clinical Oncology, Offersen et al found no difference in the rates of breast induration with moderately hypofractionated vs standard fractionated radiotherapy in women with early breast cancer or ductal carcinoma ...
Recognizing the Coexistence of Symptoms of Pancreatic Cancer
Incidence rates for pancreatic cancer were 6-fold to 10-fold higher among participants in a study who had recent-onset diabetes and weight loss.1 This led the study authors to write: “The coexistence of these symptoms should be recognized by clinicians given that both the relative and absolute...
Greater Coverage, Patient Education, and Research for Telemedicine Needed During the COVID-19 Pandemic and Beyond
Flexibilities in reimbursement that have allowed the expanded use of telemedicine during the COVID-19 pandemic should continue and be made available to more providers and patients, according to a recent statement from ASCO. ASCO Interim Position Statement: Telemedicine in Cancer Care also calls for ...
Cancer Center at Brown University Established
The Corporation of Brown University has approved the establishment of the Cancer Center at Brown. The center takes a broad-spectrum approach to research, from working to understand how cancer develops, grows, and metastasizes, to developing new therapeutics for patients in a personalized way that...
Pembrolizumab Produces Durable Responses in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Jean-Jacques Grob, MD, PhD, of Aix-Marseille University, France, and colleagues, the first interim analysis of the phase II KEYNOTE-629 trial has shown the achievement of durable responses with pembrolizumab treatment of recurrent or metastatic...
National Survey Shows Decline in Overall Youth E-Cigarette Use, Uptick in Use of Disposable Products
In september, 2020, the U.S. Food and Drug Administration (FDA), in partnership with the Centers for Disease Control and Prevention, released new data from the 2020 National Youth Tobacco Survey (NYTS). The results, published by Wang et al in Morbidity and Mortality Weekly Report (MMWR), showed 1.8 ...
Many Reasons to ‘Geriatricize’ Your Oncology Practice: Research Updates From ASCO20
“Older adults form the majority of patients with cancer.” For more than 3 decades now, almost every article, presentation, or discussion related to cancer and aging started with this statement. As I entered the field of geriatric oncology, I thought that by simply stating this fact, everyone would...
New Breast Cancer Agents and Concurrent Radiation: Risk or Benefit?
Most of the newer systemic treatments for breast cancer can be safely and effectively paired with radiation therapy—although there are some exceptions, according to Mylin A. Torres, MD, the Louisa and Rand Glenn Family Chair in Breast Cancer Research and Associate Professor of Radiation Oncology at ...
Neratinib in Previously Treated HER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial
Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...
I’ve Turned My Pain Into a New Life Purpose
The first half of 2016 was arguably the most exciting of my life. My wife, Jaione, and I had decided to leave the United Kingdom and move with our two children, Andrew, then 14, and Alba, then 10, to Denver, where I was taking on a leadership role in corporate affairs for a brewery company. By the...
With the Goal of Curing Cancer, Ezra M. Greenspan, MD, Helped Usher in the Modern Era of Chemotherapy
Born in Brooklyn on April 4, 1919, Ezra M. Greenspan, MD, did not stray far from his birthplace, spending most of his 5-decade medical career in New York. After graduating from New York University School of Medicine in 1942, he was accepted into the house training program at Mount Sinai Hospital...
Karmanos Receives $630,000 CATCH-UP Grant to Recruit Minority, Rural Patients to Clinical Trials
Researchers at the Barbara Ann Karmanos Cancer Institute have secured a 1-year, $630,000 grant from the National Cancer Institute (NCI) to help support the Institute’s clinical trials, which target underserved populations in Detroit and in the rural areas that Karmanos serves. The NCI P30 Cancer...
Irish Boy With His Scapula
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
On July 24, 2020, brexucabtagene autoleucel, a CD19-directed genetically modified autologous T-cell immunotherapy, was granted accelerated approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.1,2 Brexucabtagene autoleucel is approved with a Risk Evaluation...
Sentinel Lymph Node Biopsy and Age-Related Mutations: Therapeutic and Predictive Implications in Melanoma
Findings from a study among patients with melanoma randomly assigned to observation following removal of a positive sentinel lymph node “strongly support the therapeutic effect of the sentinel lymph node biopsy in providing long-term regional nodal disease control in the large majority of...
Age at Diagnosis May Improve Risk Stratification for Patients With Breast Cancer
Age is not just a number when it comes to prognosis for invasive breast cancer. According to data presented during the 2020 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care, age at diagnosis of breast cancer is a highly prognostic clinical variable that warrants...
Expert Point of View: Christopher Anker, MD
Christopher Anker, MD, a radiation oncologist at The University of Vermont Medical Center and Associate Professor at the Larner College of Medicine at the University of Vermont, Burlington, told The ASCO Post that although the benefit to overall survival disappeared with time likely due to a power ...
Is Infiltrating Tumor Border Configuration Linked to Poor Survival in Colon Adenocarcinoma?
Findings from a retrospective cohort study could fuel the debate over the use of adjuvant chemotherapy in stage II colon cancer, according to data presented during the virtual edition of the 2020 Society of Surgical Oncology (SSO) International Conference on Surgical Cancer Care.1 Results of the...
Azacitidine Tablets for Continued Treatment in Acute Myeloid Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 1, 2020, azacitidine tabletswere approved...
Applications of Circulating Tumor DNA Liquid Biopsy Continue to Expand in Lymphomas
Liquid biopsies using circulating tumor DNA (ctDNA) have the potential to personalize medicine for patients with lymphoma, going beyond traditional markers and risk factors to provide dynamic assessments over time. Expanded applications of ctDNA liquid biopsy beyond diagnosis include early response ...
The New Face of Medical Visits
“Good morning! I’m Dr. Saksena. It’s a pleasure to meet you.” I wave my introduction as I enter the room. Two women sit beside each other. One of them wears a mask that reads “lipstick optional,” and the other dons a surgical mask. This is a new visit for breast cancer, but I haven’t yet deciphered ...
Newer Therapeutic Approaches Improving Outcomes in Hodgkin Lymphoma
At the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference, sponsored by Emory University School of Medicine and Winship Cancer Institute, Pamela Allen, MD, Assistant Professor of Medicine at Emory, described recent trials on therapeutic approaches that are informative on this...
Efforts to Broaden Eligibility Criteria for Clinical Trials Seek to Include More Racial and Ethnic Minority Patients
A review of the 2019 Drug Trials Snapshots Report1 from the U.S. Food and Drug Administration (FDA) showed that although female participation in clinical trials grew to 72% from 56% in the FDA’s 2018 Drug Trials Snapshots Report,2 ethnic minority participation in clinical trials actually declined...
Use of ctDNA to Direct Therapy in Advanced Breast Cancer
In the phase IIa plasmaMATCH platform trial reported in The Lancet Oncology, Nicholas C. Turner, MD, and colleagues found that circulating tumor DNA (ctDNA) provided accurate genotyping that permitted selection of directed therapies in patients with advanced breast cancer. Study Details The...
AACR Releases 10th Edition of Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 10th edition of its annual Cancer Progress Report. The report highlights how cancer research, largely supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), is...
Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
The challenge in treating patients with borderline resectable pancreatic cancer is how to render tumors resectable and how to achieve the negative surgical margins that enhance long-term survival odds. Fortunately, neoadjuvant chemotherapy is helping to achieve these important goals, according to...
Study Examines Combined Impact of Aspirin, Metformin, and Statins on Lung Cancer Risk
Combined use of aspirin, metformin, and statins may be associated with decreased lung cancer incidence and mortality, according to a study published by Kang et al in the Journal of Thoracic Oncology. Study Methods The aim of this study was to investigate the associations of the three agents with...
Disease-Free Survival With Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: ADAURA Trial
As reported in The New England Journal of Medicine by Wu et al, the phase III ADAURA trial has shown significantly prolonged disease-free survival with adjuvant osimertinib vs placebo in patients with resected EGFR-mutant non–small cell lung cancer (NSCLC). These findings were also presented during ...
Olanzapine for Children and Adolescents Receiving Highly Emetogenic Chemotherapy
In a single-center Indian phase III trial reported in the Journal of Clinical Oncology, Naik et al found that the addition of olanzapine to standard antiemetic treatment significantly increased the rate of complete response (CR; defined as no vomiting or use of rescue medication) among children and ...
Impact of Neoadjuvant Endocrine Therapy and Neoadjuvant Chemotherapy on Rates of Breast‑Conserving Surgery
“Studies that have compared neoadjuvant endocrine therapy with neoadjuvant chemotherapy have shown low pathologic complete response rates with both approaches. However, the rates of breast-conserving surgery have been shown to be slightly higher with neoadjuvant endocrine therapy,” Kelly Hunt, MD,...
Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes
The Lung ART trial was designed to demonstrate whether there was any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) following complete resection and (neo)adjuvant chemotherapy. No difference in disease-free survival...
Cancer Treatment–Related Outcomes in Patients With Cancer and COVID-19
Researchers have found that certain treatments for cancer may increase the chance of death if they contract COVID-19. These findings from a multicenter study presented by Trisha Wise-Draper, MD, and colleagues at the ESMO Virtual Congress 2020 (LBA71), shed light on ways standard anticancer...
ESMO 2020: Access to Treatments and Trials Varies Widely for Patients With Cancer Across Europe
Access to cancer treatments is highly unequal across Europe, both for new drugs in development (due to disparities in access to clinical trials) and for currently approved drugs (due to disparities in health-care spending by different countries), according to results from two studies being...
Role of F-18–NaF PET/CT in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
In a phase II study reported in the Journal of Clinical Oncology, Kyriakopoulos et al found that use of quantitative total bone imaging with fluorine-18 (F-18)–sodium fluoride (NaF) positron-emission tomography/computed tomography (PET/CT) helped identify heterogeneity of response in bone lesions...
Proton Pump Inhibitor Use May Be Associated With Worse Outcomes in Patients Treated With Atezolizumab for Urothelial Cancer
Recent evidence indicates that proton pump inhibitors may cause significant changes in the gut microbiota; gut microbiota dysbiosis has been linked to reduced immune checkpoint inhibitor effectiveness. In a retrospective analysis of clinical trials investigating the immune checkpoint inhibitor...
Researchers Report on Comprehensive Analysis of Adenosquamous Carcinoma of the Pancreas
In a comprehensive analysis of adenosquamous cancer of the pancreas in preclinical models, researchers identified potential therapeutic targets for this aggressive form of pancreatic cancer. They also identified already-available agents—designed to treat other types of cancer—that may be useful in...
Overall Survival With Darolutamide in Patients With Nonmetastatic, Castration-Resistant Prostate Cancer: ARAMIS Trial
As reported in The New England Journal of Medicine by Karim Fizazi, MD, and colleagues, the phase III ARAMIS trial has shown significantly prolonged overall survival with darolutamide vs placebo in men with nonmetastatic castration-resistant prostate cancer. The previously reported primary analysis ...
Enthusiastic Response to Novel Therapies on the Horizon in Multiple Myeloma
Clinicians who treat multiple myeloma can anticipate a host of new treatments: melflufen, cereblon E3 ligase (CEL) modulators, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Kenneth C. Anderson, MD, Director of the Jerome Lipper Multiple...
Dr. Kantarjian Shares His Thoughts on Optimizing the Treatment of Adults With ALL
In the treatment of adults with acute lymphoblastic leukemia (ALL), use of newer antibodies and de-intensification of chemotherapy have greatly improved outcomes, according to Hagop Kantarjian, MD, who has been very involved in much of the research in ALL treatment. Dr. Kantarjian, Professor and...
Efficacy of High-Intensity Ultrasound Ablation for Prostate Cancer
For some patients with prostate cancer, surgery and/or radiation are considered standard treatments. However, these procedures may cause side effects, including urinary incontinence or impotency. A recent study published by Abreu et al in the Journal of Urology demonstrated that high-intensity...
National Survey Shows Decline in Overall Youth E-Cigarette Use, Uptick in Use of Disposable Products
This week, the U.S. Food and Drug Administration (FDA), in partnership with the Centers for Disease Control and Prevention, released new data from the 2020 National Youth Tobacco Survey (NYTS). The results, published by Wang et al in Morbidity and Mortality Weekly Report (MMWR), show 1.8 million...
Cryopreservation May Be Associated With Loss of Quality in Donor Stem Cell Products
During the COVID-19 pandemic, many stem cell transplant centers (including guidance from the National Marrow Donor Program [NMDP]) recommend that stem cell products be frozen for preservation. However, findings from a study by Duncan Purtill, MD, and colleagues in Blood Advances suggest that the...
Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphomas
In the TRANSCEND NHL 001 study reported in The Lancet, Jeremy S. Abramson, MD, and colleagues found that the autologous CD19-directed chimeric antigen receptor (CAR) T-cell agent lisocabtagene maraleucel (liso-cel) produced a high response rate in patients with relapsed or refractory large B-cell...
ASCO Position Statement Recommends Specific Actions for Applying Telemedicine in Cancer Care During Pandemic and Beyond
A new position statement by ASCO calls for the continuation of flexibilities in reimbursement that have allowed the expanded use of telemedicine during the COVID-19 pandemic. The statement, which also calls for further research on telemedicine’s effectiveness and benefits, offers recommendations...
Roger H. Herzig, MD, Pioneer in the Treatment of Leukemia, Dies at Age 74
More than 5 decades ago, the concept of bone marrow transplantation to treat humans with leukemia was met with varying degrees of skepticism and countless clinical failures. Yet, over those same decades, bone marrow transplantation was transformed from an insurmountable therapeutic option used in a ...
Expert Point of View: Electra D. Paskett, PhD
Formal discussant of the 2013 ASCO Plenary Abstract 2, Electra D. Paskett, PhD, Professor of Medicine at The Ohio State University, was enthusiastic about the trial results and the potential of visual inspection with acetic acid screening, as well as low-cost human papillomavirus (HPV) screening...
Simple Rapid Vinegar Screening Test Cuts Cervical Cancer Death Rates by One-Third in Rural India
In 2013, at the ASCO Annual Meeting Plenary Session, it was both surprising and encouraging in the era of personalized medicine for cancer care to hear about a simple low-tech intervention delivered by women in the community that cut the rate of death from cervical cancer in India by about...
Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the antibody-drug conjugate belantamab mafodotin-blmf was granted accelerated approval for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, ...
Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
On July 7, 2020, an oral combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine was approved for treatment of adult patients with myelodysplastic syndromes (MDS), including: Previously treated and untreated, de novo, and secondary MDS with the ...
Fitness-Based Treatment of Older Adults With Multiple Myeloma Who Are Transplant-Ineligible: The Changing Landscape
Multiple myeloma is a malignant clonal plasma cell malignancy that primarily affects older adults. Although therapeutic advances have led to improvements in disease-specific and overall survival over the past decade, age-related survival disparities continue to exist. The higher prevalence of...
